ESMO 2017 | How were biosimilars discussed at ESMO 2017?

Name: How were biosimilars discussed at ESMO 2017?
Duration: 1 min 1 s
Description: Richard Markus, MD, PhD, from Amgen, Los Angeles, CA, talks to us about a symposium at the European Society for Medical Oncology (ESMO) 2017 conference in Madrid, Spain which focused on biosimilars in cancer treatment. Dr Markus discusses ABP 980, a biosimilar of the agent trastuzumab developed by Amgen, and talks us through some of the other topics presented during the symposium.

Richard Markus • 26 Sep 2017

ESMO 2017

General ABP 980 Trastuzumab

Richard Markus, MD, PhD, from Amgen, Los Angeles, CA, talks to us about a symposium at the European Society for Medical Oncology (ESMO) 2017 conference in Madrid, Spain which focused on biosimilars in cancer treatment. Dr Markus discusses ABP 980, a biosimilar of the agent trastuzumab developed by Amgen, and talks us through some of the other topics presented during the symposium.